From the 27th – 28th of June 2022, Amgros and the Nordic Pharmaceutical Forum hosted an international workshop on negotiations on new pharmaceuticals with representatives from organizations in 9…
The Beneluxa Initiative aims to ensure sustainable access
to innovative medicine at affordable cost for our patients.
Beneluxa reaching out to other collaborations: international experience sharing on negotiations of new pharmaceuticals
Ireland, Belgium and the Netherlands complete joint HTA report on gene therapy Libmeldy
The first step in the joint reimbursement process for Libmeldy® (atidarsagene autotemcel), a gene therapy product for the treatment of children with metachromatic leukodystrophy, was successfully…
Pharmaceutical Developments on Haemophilia
This report, written by the Taskforce Horizon Scanning of the Beneluxa Initiative, describes the current situation of Haemophilia and provides an overview of new pharmaceutical developments regarding…